Atrial fibrillation is common in patients with CKD, with rates significantly higher than in the general population. CKD significantly increases thromboembolic risk above baseline and is also associated with increased risk of bleeding. The evidence to support oral anticoagulants (vitamin K antagonist or direct oral anticoagulants [DOACs]) is less robust in individuals with reduced creatinine clearance. The use of direct oral anticoagulants does represent an important opportunity and challenge in patients with impaired kidney function. This presentation by Dr. Jason Andrade reviews the literature on DOAC use with a specific focus on Edoxaban in chronic kidney disease.
Jason Andrade, M.D., FRCPC, FHRS, is a Cardiac Electrophysiologist at Vancouver General Hospital in Canada, with joint appointment at the Montreal Heart Institute. He is an Associate Professor of Medicine at the University of British Columbia (UBC), and an Assistant Professor at the Université de Montréal.
Jason Andrade, M.D., FRCPC, FHRS, is a Cardiac Electrophysiologist at Vancouver General Hospital in Canada, with joint appointment at the Montreal Heart Institute. He is an Associate Professor of Medicine at the University of British Columbia (UBC), and an Assistant Professor at the Université de Montréal.
Dr. Andrade is the Director of Electrophysiology and Director of the Atrial Fibrillation Clinic at Vancouver General Hospital (VGH). He is co-chair of the Canadian Cardiovascular Society (CCS) Atrial Fibrillation Guidelines committee, chair of the Canadian Heart Rhythm Society (CHRS) Device Committee, and medical chair for Heart Rhythm Disease for the Cardiovascular Disease Network in the province of British Columbia.
Dr. Andrade has authored over 200 scientific publications, predominantly in the domain of atrial fibrillation. His publications can be found in journals such as the New England Journal of Medicine, Circulation, Journal of the American College of Cardiology (JACC), Journal of the American Medical Association (JAMA), The Lancet, and Heart Rhythm. In addition, he is also the author of several textbooks, book chapters, and medical apps.
EDUCATION
Undergraduate: McMaster University (Summa Cum Laude)
Medical Degree: University of Ottawa, Canada (Magna Cum Laude)
Residency: University of British Columbia
Fellowship: University of British Columbia – Cardiology
Fellowship: Montreal Heart Institute – Cardiac Electrophysiology
ACCOMPLISHMENTS
Grant funding of $6,602,170 as Principal Investigator, and $74,391,112 as co-investigator
Principal investigator of the CIRCA-DOSE and the EARLY-AF multicenter randomized clinical trials
In 2021, recognized as World’s Expert in AF research
In 2021, recipient of the Clinical Faculty Award for Excellence in Research, University of British Columbia
In 2020, recipient of the Donald M Whitelaw Award, University of British Columbia
In 2019, recipient of the Alumni Achievement Award, University of Ottawa
In 2018, recipient of the Robert E. Beamish Award, Canadian Cardiovascular Society
Dr. Andrade created the slide content appearing in this presentation. He was provided an honorarium by Servier Canada to support the time spent on preparing and delivering this presentation.